Methyl-[4'-phenyloxy-(1,1'-biphenyl)-4-yl]-sulfide | 291533-88-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl-[4'-phenyloxy-(1,1'-biphenyl)-4-yl]-sulfide
• 英文别名: 4-(4-methylthiophenyl)diphenyl ether；4-(4-methylthiophenyl)diphenyl；4-(Methylthio)-4a(2)-phenoxy-1,1a(2)-biphenyl；1-methylsulfanyl-4-(4-phenoxyphenyl)benzene
• CAS: 291533-88-5
• 化学式: C₁₉H₁₆OS
• 分子量: 292.401
• InChiKey: SWCBFWXUSSLGLH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  34.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-溴联苯醚 、 2-甲硫基苯硼酸 在 四(三苯基膦)钯 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 20.0h， 以89%的产率得到Methyl-[4'-phenyloxy-(1,1'-biphenyl)-4-yl]-sulfide
  参考文献：
  名称：

  OPTICAL ELEMENT COMPOUND, OPTICAL MATERIAL, AND OPTICAL ELEMENT

  摘要：

  提供具有以下特征的光学材料有机化合物：折射率的色散特性（阿贝数（νd））和二次色散特性（θg,F）高，可见光区域的透射率高，色差校正功能性能高，其通用公式（1）或（2）表示。

  公开号：

  US20110288330A1

文献信息

• Alkenyl- and alkynl-containing metalloprotease inhibitors
  申请人：The Procter & Gamble Co.

  公开号：US06197770B1

  公开（公告）日：2001-03-06

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to the following Formula (I): where X, W, Z, A, G, R1, R2, R3, R4, R5, R5′ and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of the formula above, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一类金属蛋白酶抑制剂化合物，用于治疗由这些酶活性过度引起的疾病。具体来说，这些化合物具有以下式（I）的结构，其中X、W、Z、A、G、R1、R2、R3、R4、R5、R5'和k的含义如规范中所述。本发明还包括上述式的光学异构体、顺反异构体和对映体，以及这些化合物的药用盐、生物水解酰胺、酯和亚酰胺。还描述了包含这些化合物的药物组合物，以及使用这些化合物或药物组合物来治疗或预防与金属蛋白酶相关的疾病的方法。
• [EN] ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE METALLOPROTEASES, CONTENANT ALCENYLE ET ALCYNALE
  申请人：PROCTER & GAMBLE

  公开号：WO2000051975A1

  公开（公告）日：2000-09-08

  Disclosed are compounds which are inhibitors of metalloproteases and which are effective in treating conditions characterized by excess activity of these enzymes. In particular, the compounds have a structure according to Formula (I) where X, W, Z, A, G, R?1, R2, R3, R4, R5, R5'¿ and k have the meanings described in the specification. This invention also includes optical isomers, diastereomers and enantiomers of said formula, and pharmaceutically-acceptable salts, biohydrolyzable amides, esters, and imides thereof. Also described are pharmaceutical compositions comprising these compounds, and methods of treating or preventing metalloprotease-related maladies using the compounds or the pharmaceutical compositions.

  本发明涉及一种金属蛋白酶抑制剂化合物，其能够有效治疗由这些酶过度活性引起的疾病。特别地，该化合物具有如公式（I）所示的结构，其中X，W，Z，A，G，R1，R2，R3，R4，R5，R5'和k具有规范中描述的含义。本发明还包括该公式的光学异构体、对映异构体和对映体，以及其药学上可接受的盐、生物水解酰胺、酯和亚酰胺。还描述了包含这些化合物的药物组合物，以及使用这些化合物或药物组合物治疗或预防金属蛋白酶相关疾病的方法。
• Optical element compound, optical material, and optical element
  申请人：Canon Kabushiki Kaisha

  公开号：EP2390684A2

  公开（公告）日：2011-11-30

  An optical material organic compound having characteristics that the dispersion characteristic (Abbe number) and the secondary dispersion characteristic (θg,F) of the refractive index are high, the transmittance in the visible light region is high, and the chromatic aberration correction function delivers high performance, which represented by the general formula (1) or (2) is provided.

  提供了一种光学材料有机化合物，它具有折射率色散特性（阿贝数）和二次色散特性（θg,F）高、可见光区域透射率高、色差校正功能性能高的特点，由通式（1）或（2）表示。
• ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP1165501A1

  公开（公告）日：2002-01-02
• Method of Treating Kcnq Related Disorders Using Organozinc Compounds
  申请人：Li Min

  公开号：US20110257146A1

  公开（公告）日：2011-10-20

  The instant invention describes methods of treating KCNQ related diseases and disorders using organozinc compounds. In certain embodiments, pain is treated using Zinc Pyrithione.